Enhancing Anti-Tumor Effects of Engineered Extracellular Vesicles via Endocytosis Route Switching and Interferon Response Suppression.
Sign Up to like & getrecommendations! Published in 2025 at "Advanced science"
DOI: 10.1002/advs.202515472
Abstract: Engineered extracellular vesicles (EVs) represent a promising therapeutic strategy with many applications in cancer therapy. EVs derived from engineered tumor‐targeting killer cells, such as chimeric antigen receptor (CAR)‐T cells. However, the application of CAR‐T‐EVs is… read more here.
Keywords: extracellular vesicles; endocytosis; cd19; engineered extracellular ... See more keywords
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression
Sign Up to like & getrecommendations! Published in 2018 at "American Journal of Hematology"
DOI: 10.1002/ajh.24987
Abstract: Blinatumomab, a bi‐specific T‐cell engaging CD3‐CD19 antibody construct, has shown significant activity in patients with relapsed/refractory (R/R) B‐cell acute lymphoblastic leukemia (ALL). Despite this improvement, most patients relapse. Here, we describe the outcome of 68… read more here.
Keywords: blinatumomab failure; cd19; outcome patients; blinatumomab ... See more keywords
Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Medicine"
DOI: 10.1002/cam4.3259
Abstract: Abstract Purpose Anti‐CD19 chimeric antigen receptor T (CAR‐T) cell therapy has demonstrated remarkable efficacy for refractory and relapsed diffuse large B cell lymphoma (R/R DLBCL). However, this therapy failed in nearly 25% patients mainly due… read more here.
Keywords: cd19; anti cd19; antigen; cd20 ... See more keywords
A novel multimeric sCD19‐streptavidin fusion protein for functional detection and selective expansion of CD19‐targeted CAR‐T cells
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4657
Abstract: CARs are engineered receptors comprising an immunoglobulin single‐chain variable fragment (scFv) that identifies and binds to the target antigen, a transmembrane domain, and an intracellular T‐cell signaling domain. CD19 is a B lineage‐specific transmembrane glycoprotein… read more here.
Keywords: scd19 streptavidin; novel multimeric; fusion protein; streptavidin fusion ... See more keywords
Down‐regulation of CD19 expression inhibits proliferation, adhesion, migration and invasion and promotes apoptosis and the efficacy of chemotherapeutic agents and imatinib in SUP‐B15 cells
Sign Up to like & getrecommendations! Published in 2018 at "Cell Biology International"
DOI: 10.1002/cbin.10994
Abstract: The survival rate of childhood acute lymphoblastic leukemia (ALL) has increased while that of Philadelphia‐positive (Ph+) ALL remains low. CD19 is a B‐cell specific molecule related to the survival and proliferation of normal B cells.… read more here.
Keywords: cd19; proliferation; expression; cell ... See more keywords
Evidence of long‐lasting anti‐CD19 activity of engrafted CD19 chimeric antigen receptor–modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.2672
Abstract: Ninety percent of relapse/refractory B‐cell acute lymphatic leukemia (R/R B‐ALL) patients can achieve complete remission (CR) after CD19‐targeting chimeric antigen receptor T (CAR‐T) cell therapy. However, around 50% of them relapse in 1 year. Persistent… read more here.
Keywords: antigen receptor; cd19; phase study; leukemia ... See more keywords
Overcoming resistance to anti‐CD19 CAR T‐cell therapy in B‐cell malignancies
Sign Up to like & getrecommendations! Published in 2022 at "Hematological Oncology"
DOI: 10.1002/hon.3036
Abstract: Anti‐CD19 chimeric antigen receptor (CAR) T‐cell therapy has rapidly changed current treatment pattern, providing a better option for individuals with primary refractory or relapsed B‐cell non‐Hodgkin lymphoma (r/r B‐NHL) and B‐cell acute lymphoblastic leukemia (r/r… read more here.
Keywords: cell; cd19; cell therapy; car ... See more keywords
CD19+ tumor-infiltrating B-cells prime CD4+ T-cell immunity and predict platinum-based chemotherapy efficacy in muscle-invasive bladder cancer
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-018-2250-9
Abstract: PurposeCD19+ tumor-infiltrating B-cells (CD19+ TIB) play a crucial role in tumorigenesis, but their clinical relevance in muscle-invasive bladder cancer (MIBC) remains unknown. This study aimed to investigate the prognostic value of CD19+ TIB for post-surgery… read more here.
Keywords: mibc; cd19; cd19 tib; cancer ... See more keywords
Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers of Medicine"
DOI: 10.1007/s11684-021-0835-8
Abstract: The CD19-targeting bispecific T-cell engager blinatumomab has shown remarkable efficacy in patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. However, several studies showed that blinatumomab has a short plasma half-life due to its low molecular… read more here.
Keywords: cd3; cd19; cd3 cd19; lymphoblastic leukemia ... See more keywords
Beyond CD19 CAR-T cells in lymphoma.
Sign Up to like & getrecommendations! Published in 2021 at "Current opinion in immunology"
DOI: 10.1016/j.coi.2021.09.009
Abstract: Adoptive transfer of CD19-specific chimeric antigen receptor T-cells (CAR-T cells) has transformed the treatment paradigm of relapsed/refractory (R/R) CD19 B-cell malignancies, dramatically improving remission rates and cures in patients with chemo-refractory disease. However, the applicability… read more here.
Keywords: cd19; beyond cd19; car cells; cell ... See more keywords
Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2021 at "European journal of cancer"
DOI: 10.1016/j.ejca.2021.07.036
Abstract: INTRODUCTION Chimeric antigen receptor T-cell therapy (CART) has revolutionised treatment of haematological malignancies; however, current reporting uses a modified intention-to-treat analysis (mITT) which over-estimates efficacy. We assessed what proportion of CD19 and B-cell maturation antigen… read more here.
Keywords: cart; cd19; antigen; intention treat ... See more keywords